Primary endpoint met for sGC stimulator in HFrEF patients with worsening HF
The VICTORIA (vericiguat global study in patients with heart failure with reduced ejection fraction) phase 3 study has met its primary endpoint in patients with worsening chronic HF with reduced ejection fraction (HFrEF) following a decompensation event, defined as HF hospitalization or receiving an intravenous diuretic for HF without hospitalization. The primary endpoint was defined as the composite of time to first occurrence of CV death or HF hospitalization.
The VICTORIA trial was a randomized, placebo-controlled, parallel-group, multi-center, double-blind phase 3 study that enrolled 5050 patients and evaluated the efficacy and safety of investigational vericiguat versus placebo when given in combination with available HF therapies.
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) enzyme. In HF patients, sGS is insufficiently stimulated due to impaired nitric oxide (NO) availability resulting in myocardial and vascular dysfunction.
Treatment with vericiguat prolonged the time to first occurrence of the composite primary outcome.